Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI57ZA)

• Drug Name: TGWOOAA Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Generalized anxiety disorder	6B00	Phase 2	[1]
Social phobia	6B04	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMI57ZA

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[3]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[4]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[5]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[6]
Bis(olanzapine) pamoate monohydrate	DME76AP	Psychotic disorder	6A20-6A25	Phase 3	[7]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[8]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[9]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[10]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[11]
Heterocyclic-tetracyclic tetrahydrofuran derivative 1	DMNJVR6	N. A.	N. A.	Patented	[12]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[13]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[14]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[15]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[16]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[17]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[18]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[19]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[20]
Treximet	DMU54QB	Migraine	8A80	Approved	[21]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Antagonist	[2]
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Antagonist	[2]

References

• [1] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [2] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [3] 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
• [4] Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
• [5] Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
• [6] Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [10] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [11] Clinical pipeline report, company report or official report of Anamar.
• [12] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [15] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [16] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [17] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [18] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [19] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [20] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [21] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)